LifeMD, Inc. (NASDAQ:LFMD) Shares Sold by XTX Topco Ltd

XTX Topco Ltd trimmed its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 57.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,429 shares of the company’s stock after selling 27,341 shares during the quarter. XTX Topco Ltd’s holdings in LifeMD were worth $111,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LFMD. Geode Capital Management LLC raised its stake in shares of LifeMD by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock worth $4,071,000 after buying an additional 2,984 shares during the period. Wells Fargo & Company MN raised its stake in shares of LifeMD by 44.7% during the 4th quarter. Wells Fargo & Company MN now owns 18,732 shares of the company’s stock worth $93,000 after buying an additional 5,791 shares during the period. Renaissance Technologies LLC raised its stake in shares of LifeMD by 45.2% during the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company’s stock worth $2,524,000 after buying an additional 158,796 shares during the period. Raymond James Financial Inc. acquired a new position in shares of LifeMD during the 4th quarter worth approximately $473,000. Finally, Barclays PLC raised its stake in shares of LifeMD by 15.8% during the 4th quarter. Barclays PLC now owns 56,773 shares of the company’s stock worth $281,000 after buying an additional 7,756 shares during the period. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Stock Down 4.2%

Shares of LFMD opened at $6.60 on Friday. The company has a debt-to-equity ratio of 9.21, a quick ratio of 0.72 and a current ratio of 0.77. LifeMD, Inc. has a one year low of $3.99 and a one year high of $15.84. The stock has a market capitalization of $312.97 million, a price-to-earnings ratio of -31.43 and a beta of 1.72. The stock has a 50 day moving average price of $11.41 and a 200 day moving average price of $8.52.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. BTIG Research upped their target price on LifeMD from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, June 18th. HC Wainwright reduced their target price on LifeMD from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. KeyCorp reduced their target price on LifeMD from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Wednesday, August 6th. Wall Street Zen cut LifeMD from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Lake Street Capital dropped their price target on LifeMD from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, LifeMD presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.86.

Insider Transactions at LifeMD

In related news, CFO Marc David Benathen sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $14.01, for a total transaction of $700,500.00. Following the completion of the sale, the chief financial officer directly owned 339,554 shares in the company, valued at approximately $4,757,151.54. The trade was a 12.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total value of $334,500.00. Following the completion of the sale, the chief executive officer owned 2,500,721 shares of the company’s stock, valued at approximately $33,459,646.98. The trade was a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 275,000 shares of company stock valued at $3,564,550 over the last ninety days. Company insiders own 18.40% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.